ArticleJournal of thoracic disease2019

Management of non-small cell lung cancer harboring epidermal growth factor receptor mutations in the era of first-line osimertinib.

Taiki Hakozaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.